Dietary supplements for preventing postnatal depression

Background Postnatal depression is a medical condition that affects many women and the development of their infants. There is a lack of evidence for treatment and prevention strategies that are safe for mothers and infants. Certain dietary deficiencies in a pregnant or postnatal woman's diet ma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane database of systematic reviews 2013-10, Vol.2013 (10), p.CD009104-CD009104
Hauptverfasser: Miller, Brendan J, Murray, Linda, Beckmann, Michael M, Kent, Terrence, Macfarlane, Bonnie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Postnatal depression is a medical condition that affects many women and the development of their infants. There is a lack of evidence for treatment and prevention strategies that are safe for mothers and infants. Certain dietary deficiencies in a pregnant or postnatal woman's diet may cause postnatal depression. By correcting these deficiencies postnatal depression could be prevented in some women. Specific examples of dietary supplements aimed at preventing postnatal depression include: omega‐3 fatty acids, iron, folate, s‐adenosyl‐L‐methionine, cobalamin, pyridoxine, riboflavin, vitamin D and calcium. Objectives To assess the benefits of dietary supplements for preventing postnatal depression either in the antenatal period, postnatal period, or both. Search methods We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013). Selection criteria Randomised controlled trials, involving women who were pregnant or who had given birth in the previous six weeks, who were not depressed or taking antidepressants at the commencement of the trials. The trials could use as intervention any dietary supplementation alone or in combination with another treatment compared with any other preventive treatment, or placebo, or standard clinical care. Data collection and analysis Two review authors independently assessed trials for inclusion and assessed the risk of bias for the two included studies. Two review authors extracted data and the data were checked for accuracy. Main results We included two randomised controlled trials. One trial compared oral 100 microgram (µg) selenium yeast tablets with placebo, taken from the first trimester until birth. The trial randomised 179 women but outcome data were only provided for 85 women. Eighty‐three women were randomised to each arm of the trial. Sixty‐one women completed the selenium arm, 44 of whom completed an Edinburgh Postnatal Depression Scale (EPDS). In the placebo arm, 64 women completed the trial, 41 of whom completed an EPDS. This included study (n = 85) found selenium had an effect on EPDS scores but did not reach statistical significance (P = 0.07). There was a mean difference (MD) of ‐1.90 (95% confidence interval (CI) ‐3.92 to 0.12) of the self‐reported EPDS completed by participants within eight weeks of delivery. There was a high risk of attrition bias due to a large proportion of women withdrawing from the study or not completing an EPDS. This included study did not report
ISSN:1465-1858
1465-1858
1469-493X
DOI:10.1002/14651858.CD009104.pub2